Abogen is pleased to announce the appointment of Dr. Iain McFadyen as the company’s Chief AI Officer and a member of Scientific Advisory Board. In this role, Dr. McFadyen will spearhead Abogen’s digital platform and AI technologies to accelerate the innovation and translation of RNA therapeutics.

Dr. Iain McFadyen brings with him a wealth of experience and deep expertise in computational sciences, AI-driven drug R&D as well as digital platform development. He served as Chief Data Science Officer roles at Tessera Therapeutics and LifeMine Therapeutics, where he led multidisciplinary specialist teams in the construction of comprehensive, end-to-end computational infrastructures. Prior to that, Dr. McFadyen served as Vice President at Moderna Therapeutics, where he conceived and built the company’s Computational Science function from the ground up, including establishing Moderna’s ML/AI capabilities and pioneering work in mRNA sequence design. He also established the Next Generation Analytics function for NGS analysis and led the creation of custom mRNA-focused informatics platforms — thereby setting a new industry standard in mRNA innovation.

Dr. McFadyen received his Bachelor's degree in Medicinal and Pharmaceutical Chemistry from Loughborough University and a PhD degree in Molecular Pharmacology from the University of Michigan.

“Iain and I have worked together in the past, his knowledge and leadership are widely recognized by the field, and we are so thrilled to welcome him to the Abogen team,” stated Dr. Bo Ying, CEO of Abogen. “Over the past few years, Abogen has developed a fully automated mRNA production and QC lab capable of generating high‑quality data to support the training of our in‑house algorithms. As our platform technologies continue to mature and our clinical pipeline progresses, AI has become a critical foundation for the development of next-generation mRNA and LNP technology, enabling more precise and individualized therapies. We believe Dr. Iain McFadyen is exceptionally well-suited to lead us into this exciting new chapter. His expertise and leadership will be instrumental in positioning us at the forefront of impactful RNA innovation.”

“I am truly impressed by Abogen’s innovative mRNA platform and robust R&D capabilities,” said Dr. Iain McFadyen, “I am grateful for the opportunity to contribute my experience in computational science, AI‑led platform strategy, and the digitalization of drug discovery at such a dynamic company. I’m looking forward to collaborating closely with the R&D team and driving AI innovation to advance RNA‑based therapies.”